[1]
Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005 Oct:103(4):695-703
[PubMed PMID: 16192761]
[2]
Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007 Feb:106(2):283-8
[PubMed PMID: 17264722]
[3]
Thompson CA. Sugammadex approved to reverse NMBA effects. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016 Feb 1:73(3):100. doi: 10.2146/news160009. Epub
[PubMed PMID: 26796899]
[4]
Cameron KS, Clark JK, Cooper A, Fielding L, Palin R, Rutherford SJ, Zhang MQ. Modified gamma-cyclodextrins and their rocuronium complexes. Organic letters. 2002 Oct 3:4(20):3403-6
[PubMed PMID: 12323029]
Level 3 (low-level) evidence
[5]
Asztalos L, Szabó-Maák Z, Gajdos A, Nemes R, Pongrácz A, Lengyel S, Fülesdi B, Tassonyi E. Reversal of Vecuronium-induced Neuromuscular Blockade with Low-dose Sugammadex at Train-of-four Count of Four: A Randomized Controlled Trial. Anesthesiology. 2017 Sep:127(3):441-449. doi: 10.1097/ALN.0000000000001744. Epub
[PubMed PMID: 28640017]
Level 1 (high-level) evidence
[6]
Nag K, Singh DR, Shetti AN, Kumar H, Sivashanmugam T, Parthasarathy S. Sugammadex: A revolutionary drug in neuromuscular pharmacology. Anesthesia, essays and researches. 2013 Sep-Dec:7(3):302-6. doi: 10.4103/0259-1162.123211. Epub
[PubMed PMID: 25885973]
[7]
Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesthesia and analgesia. 2010 Jan 1:110(1):64-73. doi: 10.1213/ane.0b013e3181ac53c3. Epub 2009 Aug 27
[PubMed PMID: 19713265]
Level 1 (high-level) evidence
[8]
Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003 Sep:99(3):632-7; discussion 6A
[PubMed PMID: 12960547]
[9]
Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia and analgesia. 2007 Mar:104(3):575-81
[PubMed PMID: 17312211]
[10]
Pühringer FK, Gordon M, Demeyer I, Sparr HJ, Ingimarsson J, Klarin B, van Duijnhoven W, Heeringa M. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. British journal of anaesthesia. 2010 Nov:105(5):610-9. doi: 10.1093/bja/aeq226. Epub 2010 Sep 28
[PubMed PMID: 20876699]
[11]
Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008 Aug:109(2):188-97. doi: 10.1097/ALN.0b013e31817f5bc7. Epub
[PubMed PMID: 18648227]
Level 1 (high-level) evidence
[12]
Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core evidence. 2013:8():57-67. doi: 10.2147/CE.S35675. Epub 2013 Sep 25
[PubMed PMID: 24098155]
[13]
Geldner G, Niskanen M, Laurila P, Mizikov V, Hübler M, Beck G, Rietbergen H, Nicolayenko E. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012 Sep:67(9):991-8. doi: 10.1111/j.1365-2044.2012.07197.x. Epub 2012 Jun 14
[PubMed PMID: 22698066]
Level 1 (high-level) evidence
[14]
Llauradó S, Sabaté A, Ferreres E, Camprubí I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012 Jul:117(1):93-8. doi: 10.1097/ALN.0b013e3182580409. Epub
[PubMed PMID: 22549697]
[15]
Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011 Aug:66(8):721-5. doi: 10.1111/j.1365-2044.2011.06782.x. Epub 2011 Jun 21
[PubMed PMID: 21692760]
[16]
Togioka BM, Yanez D, Aziz MF, Higgins JR, Tekkali P, Treggiari MM. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. British journal of anaesthesia. 2020 May:124(5):553-561. doi: 10.1016/j.bja.2020.01.016. Epub 2020 Mar 2
[PubMed PMID: 32139135]
Level 1 (high-level) evidence
[17]
Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. British journal of anaesthesia. 2008 May:100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2
[PubMed PMID: 18385265]
[18]
Hunter JM, Naguib M. Sugammadex-induced bradycardia and asystole: how great is the risk? British journal of anaesthesia. 2018 Jul:121(1):8-12. doi: 10.1016/j.bja.2018.03.003. Epub 2018 Apr 13
[PubMed PMID: 29935599]
[19]
Baronos S,Selvaraj BJ,Liang M,Ahmed K,Yarmush J, Sugammadex-induced bronchospasm during desflurane anaesthesia. British journal of anaesthesia. 2019 Jul;
[PubMed PMID: 31027913]
[20]
Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, Hunter JM. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. British journal of anaesthesia. 2010 Jan:104(1):31-9. doi: 10.1093/bja/aep340. Epub
[PubMed PMID: 20007792]
[21]
Cammu G, Van Vlem B, van den Heuvel M, Stet L, el Galta R, Eloot S, Demeyer I. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. British journal of anaesthesia. 2012 Sep:109(3):382-90. doi: 10.1093/bja/aes207. Epub 2012 Jun 24
[PubMed PMID: 22732111]
[22]
Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, Hermens Y, Mirakhur RK. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009 Feb:110(2):284-94. doi: 10.1097/ALN.0b013e318194caaa. Epub
[PubMed PMID: 19194156]
[23]
Pühringer FK, Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in Caesarean section patients: a series of seven cases. British journal of anaesthesia. 2010 Nov:105(5):657-60. doi: 10.1093/bja/aeq227. Epub 2010 Aug 24
[PubMed PMID: 20736231]
Level 3 (low-level) evidence
[24]
Nauheimer D, Kollath C, Geldner G. [Modified rapid sequence induction for Caesarian sections : case series on the use of rocuronium and sugammadex]. Der Anaesthesist. 2012 Aug:61(8):691-5. doi: 10.1007/s00101-012-2065-6. Epub
[PubMed PMID: 22875060]
Level 2 (mid-level) evidence
[26]
Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, Nakatsuka I, Takeda J. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesthesia and analgesia. 2013 Aug:117(2):345-51. doi: 10.1213/ANE.0b013e3182999672. Epub 2013 Jun 11
[PubMed PMID: 23757472]
[27]
Naguib M, Brull SJ, Kopman AF, Hunter JM, Fülesdi B, Arkes HR, Elstein A, Todd MM, Johnson KB. Consensus Statement on Perioperative Use of Neuromuscular Monitoring. Anesthesia and analgesia. 2018 Jul:127(1):71-80. doi: 10.1213/ANE.0000000000002670. Epub
[PubMed PMID: 29200077]
Level 3 (low-level) evidence
[28]
Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clinical drug investigation. 2011:31(2):101-11. doi: 10.2165/11584730-000000000-00000. Epub
[PubMed PMID: 21067251]
[29]
Moon YJ, Kim SH, Kim JW, Lee YK, Jun IG, Hwang GS. Comparison of postoperative coagulation profiles and outcome for sugammadex versus pyridostigmine in 992 living donors after living-donor hepatectomy. Medicine. 2018 Mar:97(11):e0129. doi: 10.1097/MD.0000000000010129. Epub
[PubMed PMID: 29538210]
[30]
Dirkmann D, Britten MW, Pauling H, Weidle J, Volbracht L, Görlinger K, Peters J. Anticoagulant Effect of Sugammadex: Just an In Vitro Artifact. Anesthesiology. 2016 Jun:124(6):1277-85. doi: 10.1097/ALN.0000000000001076. Epub
[PubMed PMID: 26950705]
[31]
Miyazaki Y, Sunaga H, Kida K, Hobo S, Inoue N, Muto M, Uezono S. Incidence of Anaphylaxis Associated With Sugammadex. Anesthesia and analgesia. 2018 May:126(5):1505-1508. doi: 10.1213/ANE.0000000000002562. Epub
[PubMed PMID: 29064876]
[32]
Min KC, Woo T, Assaid C, McCrea J, Gurner DM, Sisk CM, Adkinson F, Herring WJ. Incidence of hypersensitivity and anaphylaxis with sugammadex. Journal of clinical anesthesia. 2018 Jun:47():67-73. doi: 10.1016/j.jclinane.2018.03.018. Epub 2018 Apr 3
[PubMed PMID: 29621739]
[33]
Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, Maktabi M, Lee J, Kwo J, Pino R, Sabouri AS, McGovern F, Staehr-Rye AK, Eikermann M. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. British journal of anaesthesia. 2015 Nov:115(5):743-51. doi: 10.1093/bja/aev104. Epub 2015 May 2
[PubMed PMID: 25935840]
Level 1 (high-level) evidence
[34]
Herbstreit F, Peters J, Eikermann M. Impaired upper airway integrity by residual neuromuscular blockade: increased airway collapsibility and blunted genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2009 Jun:110(6):1253-60. doi: 10.1097/ALN.0b013e31819faa71. Epub
[PubMed PMID: 19417617]
[35]
Carron M, Zarantonello F, Lazzarotto N, Tellaroli P, Ori C. Role of sugammadex in accelerating postoperative discharge: A meta-analysis. Journal of clinical anesthesia. 2017 Jun:39():38-44. doi: 10.1016/j.jclinane.2017.03.004. Epub 2017 Mar 23
[PubMed PMID: 28494905]
Level 1 (high-level) evidence
[36]
Oh TK, Oh AY, Ryu JH, Koo BW, Song IA, Nam SW, Jee HJ. Retrospective analysis of 30-day unplanned readmission after major abdominal surgery with reversal by sugammadex or neostigmine. British journal of anaesthesia. 2019 Mar:122(3):370-378. doi: 10.1016/j.bja.2018.11.028. Epub 2019 Jan 2
[PubMed PMID: 30770055]
Level 2 (mid-level) evidence
[37]
Krause M, McWilliams SK, Bullard KJ, Mayes LM, Jameson LC, Mikulich-Gilbertson SK, Fernandez-Bustamante A, Bartels K. Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design. Anesthesia and analgesia. 2020 Jul:131(1):141-151. doi: 10.1213/ANE.0000000000004505. Epub
[PubMed PMID: 31702700]
[38]
Alday E, Muñoz M, Planas A, Mata E, Alvarez C. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2019 Nov:66(11):1328-1337. doi: 10.1007/s12630-019-01419-3. Epub 2019 Jun 4
[PubMed PMID: 31165457]
Level 1 (high-level) evidence
[39]
Tevis SE, Kennedy GD. Postoperative Complications: Looking Forward to a Safer Future. Clinics in colon and rectal surgery. 2016 Sep:29(3):246-52. doi: 10.1055/s-0036-1584501. Epub
[PubMed PMID: 27582650]
[40]
Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtefeld M, Senagore AJ. Postoperative ileus: it costs more than you expect. Journal of the American College of Surgeons. 2010 Feb:210(2):228-31. doi: 10.1016/j.jamcollsurg.2009.09.028. Epub 2009 Nov 18
[PubMed PMID: 20113944]
[41]
Deljou A, Schroeder DR, Ballinger BA, Sprung J, Weingarten TN. Effects of Sugammadex on Time of First Postoperative Bowel Movement: A Retrospective Analysis. Mayo Clinic proceedings. Innovations, quality & outcomes. 2019 Sep:3(3):294-301. doi: 10.1016/j.mayocpiqo.2019.06.003. Epub 2019 Aug 23
[PubMed PMID: 31485567]
Level 2 (mid-level) evidence
[42]
Chae YJ, Joe HB, Oh J, Lee E, Yi IK. Thirty-Day Postoperative Outcomes Following Sugammadex Use in Colorectal Surgery Patients; Retrospective Study. Journal of clinical medicine. 2019 Jan 16:8(1):. doi: 10.3390/jcm8010097. Epub 2019 Jan 16
[PubMed PMID: 30654513]
Level 2 (mid-level) evidence
[43]
Sen A, Erdivanli B, Tomak Y, Pergel A. Reversal of neuromuscular blockade with sugammadex or neostigmine/atropine: Effect on postoperative gastrointestinal motility. Journal of clinical anesthesia. 2016 Aug:32():208-13. doi: 10.1016/j.jclinane.2016.03.010. Epub 2016 Apr 20
[PubMed PMID: 27290978]